What is the best treatment for patients with human papillomavirus–positive and –negative oropharyngeal cancer?
Article first published online: 27 FEB 2014
© 2014 American Cancer Society
Volume 120, Issue 10, pages 1462–1470, 15 May 2014
How to Cite
Urban, D., Corry, J. and Rischin, D. (2014), What is the best treatment for patients with human papillomavirus–positive and –negative oropharyngeal cancer?. Cancer, 120: 1462–1470. doi: 10.1002/cncr.28595
- Issue published online: 6 MAY 2014
- Article first published online: 27 FEB 2014
- Manuscript Accepted: 20 DEC 2013
- Manuscript Revised: 17 DEC 2013
- Manuscript Received: 18 OCT 2013
- head and neck cancer;
- squamous cell carcinoma;
- oropharyngeal cancer;
- human papillomavirus
The discovery that the human papilloma virus (HPV) is associated with a high and increasing percentage of oropharyngeal squamous cell carcinomas (SCCs) is among the most significant advances in the field of head and neck oncology. HPV-positive oropharyngeal cancer (HPVOPC) has clinical, etiologic, pathologic, and molecular features that distinguish it from HPV-negative disease. Increasingly, HPVOPC is being diagnosed in clinical practice because of the easy availability of p16 immunohistochemistry, a surrogate marker of HPV. The superior prognosis of HPVOPC has led to a reexamination of treatment approaches, and clinical trials are currently investigating strategies to deintensify treatment to reduce acute and late toxicity while preserving efficacy. This is of particular interest in low-risk patients. Unfortunately, patients with HPV-negative tumors still have high rates of locoregional failure and more efficacious treatments are required. This review of oropharyngeal SCC focuses on current and investigational treatment strategies in patients with both HPV-positive and HPV-negative oropharyngeal SCC. Cancer 2014;120:1462–1470. © 2014 American Cancer Society.